Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Under the agreement, AbbVie will grant patent licenses to Amgen for the sale of its drug on a country-by-country basis. As part of the settlement, the companies have dismissed all pending litigation over the drug.
Neither company disclosed the financial terms of the agreement, but Amgen indicated that it will launch its drug, to be marketed as Amgevita, in the European Union on October 16, 2018. In the United States, the biosimilar will be marketed under a slightly different name—Amjevita—and will launch on January 31, 2023.
"We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide. [Amgevita] will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market," said Scott Foraker, vice president and general manager of biosimilars at Amgen.
The FDA approved Amgen’s biosimilar drug in September 2016, and the European Commission authorized its marketing in March 2017. However, litigation over AbbVie’s patents for the innovator Humira had made it unclear when the biosimilar would become commercially available. AbbVie had sued Amgen for infringing on 10 of its patents covering adalimumab.
News of today’s settlement raises questions as to whether a similar agreement could be forthcoming for AbbVie and Boehringer Ingelheim (BI), which saw its own biosimilar adalimumab, Cyltezo, approved by the FDA in August and recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this month.
In Cyltezo’s case, AbbVie filed an even more extensive lawsuit against BI, saying that BI would infringe on 74 patents. The first phase of BPCIA litigation over Cyltezo’s alleged infringement will involve 8 of those patents, as BI did not consent to AbbVie’s proposal of a single wave of patent litigation.
The reference Humira is the top selling drug in the world, earning AbbVie $16.08 billion in 2016. While its global sales grew by 14.7% last year, biosimilar competition and the introduction of new drugs are expected to erode its dominance in the rheumatoid arthritis and inflammatory disease marketplace.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.